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Abstract
Background: Cardiovascular diseases(CVD), specifically ischaemic heart disease(IHD), are the main causes of death
in industrialized countries. Statins are not usually prescribed in the most appropriate way. To ensure the correct
prescription of these drugs, it is necessary to develop, disseminate and implement clinical practice guidelines
(CPGs), and subsequently evaluate them.
The main objective of this study is to evaluate the effectiveness of the implementation of consensual Lipid-
lowering drugs (LLD) prescription guidelines in hospital and primary care settings, to improve the control of Low-
Density Lipoprotein Cholesterol (LDL-C) levels in patients with IHD in the Terres de l’Ebre region covered by the
Catalonian Health Institute. Secondary objectives are to assess the improvement of the prescription profile of these
LLDs, to assess cardiovascular morbimortality and the professional profile and participant centre characteristics that
govern the control of LDL-C.
Methods/Design: Design: Quasi-experimental uncontrolled before and after study. The intervention consists of the
delivery of training strategies for guideline implementation (classroom clinical sessions and on-line courses) aimed
at primary care and hospital physicians. The improvement in the control of LDL-C levels in the 3,402 patients with
IHD in our territory is then assessed.
Scope: Primary care physicians from 11 basic health areas(BHAs) and two hospital services (internal medicine and
cardiology).
Sample: 3,402 patients registered with IHD in the database of the Catalan Institute of Health(E-cap) before
December 2008 and patients newly diagnosed during 2009-2010.
Variables: Percentage of patients achieving good control of LDL-C, measured in milligrams per decilitre. The aim of
the intervention is to achieve levels of LDL-C < 100 mg/dl in patients with IHD. Secondary variables measure type
and time of diagnosis of IHD, type and dose of prescribed cholesterol-lowering drugs, level of physician
participation in training activities and their professional profile.
Discussion: The development of prescription guidelines previously agreed by various medical specialists involved
in treating IHD patients have usually improved drug prescription. The guideline presented in this study aims to
improve the control of LDL-C by training physicians through presential and on-line courses on the dissemination
of this guideline, and by providing feedback on their personal results a year after this training intervention.
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CVD, specifically IHD, is the leading cause of death in
Europe overall, and specifically in Spain. It is also
responsible for high morbidity and high economic
health care costs. Therefore, it is of particular concern
in the health plans in industrialized countries [1]. At
present, CVD prevention is based on the detection and
treatment of modifiable risk factors, including dyslipi-
daemia [1-4].
For DL, lipid-lowering treatment aims not only to
reduce levels of the different blood lipids, but also to
reduce the CV morbidity and mortality associated with
them. It is considered that the value of LDL-C should
determine the start of lipid-lowering therapy since there
is strong evidence that such a reduction leads to a
directly proportional reduction in CV risk [2,5]. Thus,
hypercholesterolaemia is accompanied by a high preva-
l e n c eo fc o r o n a r yd i s e a s ei nb o t hs e x e s ,e x p l a i n i n g
19.4% of coronary events in men and 20.1% in women.
The information currently available about the risk attri-
butable to each of the cardiovascular risk factors
(CVRFs) in the Spanish population is limited. Although
w ek n o wt h ep r e v a l e n c eo ft h e s eC V R F sw ed on o t
know very much about their control [6].
In order to improve the management of CVD and
IHD various organizations have developed a number of
CPGs and Expert Consensus Documents in recent years.
These documents review the scientific evidence related
to IHD, CVD CVRFs and CV prevention, critically
assess the diagnostic and therapeutic procedures, and
establish recommendations based on the profile of effi-
cacy, safety, convenience and cost of a procedure or
treatment, and assess the risk/benefit [1-3,5,7]. After
developing these CPGs it is imperative to translate the
knowledge they yield to professionals and thereby to
clinical practice. Unfortunately, it is well known that
professionals who should be using these CPGs are often
unaware of them or simply do not implement them
[8-10]. This is why it is necessary to develop strategies
for CPG implementation that can overcome the difficul-
ties and barriers in the setting in which they are going
to be used. These strategies have had a favourable influ-
ence on clinical outcomes. It is also essential to make a
final analysis of the results using polls and registers to
verify whether physicians are implementing the recom-
mendations of the guidelines in their clinical practice
and to assess their impact on patients’ clinical outcomes
[8-10].
Some studies have aimed to determine the theoretical
applicability of the GPCs by comparing results of clini-
cal practice in the field of the DL and primary care. The
RESPECT study [11] has shown moderate levels of
agreement between theoretical calculations and routine
clinical practice. Several clinical trials, in which the
intervention consisted of the dissemination of guidelines
for hypertension and DL, have reported an increase in
the prescription of drugs, but no improvement in the
quality of the management of hypertension and DL
patients [11,12]. Another study of CPG implementation
in primary care and CVD has shown the quality of care
to be suboptimal. In this study, only 15-40% of patients
achieved the treatment goals. Medical education inter-
ventions and subsequent audits offer improvements but
there remains a gap between the recommendations and
the reality [13].
In the health region of Terres de l’Ebre, there is parti-
cular interest in and concern to improve the manage-
ment of patients with CVD. The Preseap study has
recently been carried out in our area [14]. This aimed to
improve the management of patients in secondary pre-
vention of CVD, through a programme of intensive con-
trol based on medical visits by patients in their health
centre. The results showed no differences between this
group of patients and a control group who made regular
visits [14,15]. In addition, the factors determining the
control of LDL-C levels have been studied in patients
with CVD. It was found that control of these factors dif-
f e r e dw i t h i na n db e t w e e nt h ev a r i o u ss t u d i e s ,a no u t -
come that should be borne in mind when applying the
current recommendations for achieving therapeutic
goals in secondary prevention [16].
For this reason, a collaborative action between primary
and hospital care units was instigated in 2008 to coordi-
nate, harmonise and improve the management of
patients with CVD in our area. Amongst these actions, a
multidisciplinary CPG for the treatment of DL in sec-
ondary prevention of CVD has been planned, with tech-
nical advice from the Catalan Institute Pharmacology
Foundation (FICF).
In this CPG, very general recommendations are made
about the control of various CVRFs, and the non-phar-
macological (lifestyle changes) and pharmacological DL
treatments (especially hypercholesterolaemia) are also
described in detail. In addition, the efficacy, safety, con-
venience, cost and risk-benefit ratio of various therapeu-
tic interventions and their role in secondary prevention
are evaluated. It also provides several tables for guidance
to facilitate drug prescription by physicians based on the
goals of LDL-C control for secondary prevention.
Finally, an algorithm is proposed to improve patient
control and follow-up.
In recent years, the need to promote research into pri-
mary care has become increasingly recognised, as exem-
plified by the many studies addressing the development
of strategies to improve prescription quality and imple-
mentation of GPCs [10]. One of the great challenges
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sional involved adhere closely to the GPCs [7,17-20].
Objectives
The main objective is to evaluate the implementation
effectiveness of a set of lipid-lowering treatment guide-
lines in the primary care and hospital settings, and
thereby to improve LDL-C lipid control in patients with
IHD throughout the Terres de l’Ebre Region served by
the Catalonian Institute of Health.
Secondary objectives
- To evaluate the implementation effectiveness of the
guidelines for improving the profile (type and dose) of
LLD prescribed by physicians to patients with IHD.
- To assess CV morbidity and mortality.
- To determine how professional profile influences the
impact and effectiveness of the intervention.
Methods/Design
Study design
The design is a quasi-experimental uncontrolled
before-and-after study, investigating patients seen by
physicians in primary care centres and hospitals in the
Terres de l’Ebre region covered by the Catalan Insti-
tute of Health.
Setting
All the Primary Care Areas (PCAs) of the Terres de
l’Ebre provincial Health Region of Tarragona, Catalonia,
Spain, have agreed to participate in this study. This will
include physicians from the eleven PCAs and cardiolo-
gists and internal medicine physicians from the Hospital
de Tortosa Verge de la Cinta.
Study period
The study will be undertaken between January 2009 and
January 2012.
Study sample
The sample will include those patients registered in the
database (e-cap programme) with different IHD-related
diagnoses: myocardial infarction, stable angina or
unstable coronary syndrome, and chronic myocardial
ischaemia. In all, 3,402 patients (registered up to
December 2008) will participate in this study, along
with those newly diagnosed with IHD who have been
registered in the e-cap programme during 2009 and
2010. All patients who do not meet the criteria of the
attended population (i.e., those not making a minimum
of three primary care visits over the previous two years,
and at least one visit in the last year) will be excluded
from the study. Patients with a terminal or serious ill-
ness will also be excluded.
Intervention
The intervention has been designed to use different stra-
tegies for implementing the CPG in an attempt to
increase the efficiency of lipid-lowering prescription for
better control of DL in the patients in our health region.
The intervention will be carried out by medical profes-
sionals through double training sessions with a brief
refresher session of the GPC and provision of feedback
of their personal results a year after the initial
intervention.
The intervention targeted at the physician has two
components
a) Presential training sessions and interactive workshops
Doctors from the 11 primary care centres and the two
hospital services (Cardiology and Internal Medicine) will
be informed about the CPG and the various measures of
secondary coronary heart disease prevention (how to
achieve the target levels of LDL-C). Two doctors (one
from primary care and the other from a hospital), pre-
viously trained by the research team, will lead the ses-
sions that will take place in each primary care centre
and hospital service. Two types of session will be held:
- An initial two-hour training session.
- A one-hour refresher session, a year after the initial
training session, where the initial results will be pre-
sented and attendees will be reminded of the key points.
b) On-line training course
On a voluntary basis, physicians involved in the study
may take a 20-hour on-line course. Teachers will be
physicians from the FICF.
Measurements
First, a database will be set up to contain the cases diag-
nosed with IHD, wherein every case will be linked to
the primary care physician and health centre. This will
allow us to correlate the patient’s degree of disease con-
trol with their sociodemographic characteristics, doctor’s
profile and primary care centre characteristics. We will
analyze the number of patients with LDL cholesterol
control (patients with LDL cholesterol < 100 mg/dl),
mean of controlled patients (with LDL cholesterol < 100
mg/dl) per physician, number of patients with IHD by
physician, types of IHD and years of disease progression.
Patients with and without lipid-lowering therapy,
treatment type, dosage and proper treatment of IHD
(numbers of patients with: anti-aggregation vs. anticoa-
gulation, beta blockers and angiotensin-converting
enzyme inhibitors (ACEI)) will also be analysed.
The number of laboratory tests per patient before and
after the intervention will be taken into account to
assess the degree of patient control.
The profile of the clinicians who receive the interven-
tion will include variables such as their attendance on
the classroom course, completion of the on-line course,
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status, specialist by residency training system or not,
and assistance quality standards (scored from 0 - 1000
on the basis of the recommendations of an expert
group. This number is determined by the level of detec-
tion and control of the most prevalent diseases), stan-
dard of drug prescription (scored from 0 - 130
according to the annual prescription standards set by an
expert panel). Finally, characteristics of each primary
care centre, such as population assignment, population
served, number of patients per doctor, status as a teach-
ing or non-teaching centre, location in a rural or urban
area, and whether a referral hospital, will also be
examined.
Main independent variable
Percentage of patients who achieve a good control of
LDL-C, measured in milligrams/decilitre (mg/dl). The
control goal for IHD patients is LDL-c < 100 mg/dl.
At the beginning of the study, a patient will be consid-
ered to be controlled if the most recent measured level
of LDL-C (in 2008) is < 100 mg/dl.
Secondary variables
IHD - Type: Acute myocardial infarction, stable and
unstable angina, acute coronary syndrome and chronic
myocardial ischaemia.
- Time since disease diagnosis (diagnosis date)
LLD - Type of the LLD(s) prescribed.
- Doses of the LLD(s) prescribed.
Number of laboratory tests of LDL-C
- Number of laboratory tests of LDL-C performed
before (in 2009), during (2010-2011) and after the inter-
vention (in 2012) in patients with an IHD diagnosis.
Assessment of professional participation
- Number of physicians who have attended the presen-
tial (classroom) session.
- Number of physicians who have undertaken the on-
line course.
Sociodemographic characteristics of physicians
- Hospital or primary care physician, gender, age,
employment status (steady or locum), specialist by resi-
dency training system or not, Catalan Health Institute
referral hospital or not, teaching unit, assistance quality
standards and drug prescription standard.
Characteristics of Primary Care Centres
Drug prescription quality standard, assistance quality
standards, assigned population, attended population,
number of patients by doctor, teaching or non-teaching
primary attention centre, rural or urban location, and
referral hospital status.
Statistical analysis
1. Sample size
At present, the percentage of good control of LDL-C
levels of patients with IHD in our area is around 35%
(assistance quality standards results for our area calcu-
lated from the primary care information services of Cat-
alonia Institute of Health). Considering this value as a
starting point, we estimate that it would be reasonable
to expect an increase in control efficiency of at least
10% following this intervention.
We assume an average of 25 patients per physician
with a 95% confidence interval (CI) of 0.05. Accepting
an alpha error of 0.05 and 90% statistical power for
bilateral contrasts and assuming a 20% loss rate, would
require an estimated sample size of 2,761 patients. To
achieve this sample, given a 2.4% prevalence of IHD in
our population of 142,549 adult inhabitants, 115,042
health service users will be needed.
2. Analytical strategy
The statistical analysis will be preceded by an examina-
tion of outliers, data cleaning, identification and label-
ling of missing and/or unenforceable values, and
labelling of variables and variable categories.
Variables will be summarised as the mean and 95% CI
for continuous variables, and as absolute values or per-
centages and 95% CI for categorical variables. Statistical
significance will be concluded for values of p < 0.05.
T h ed i f f e r e n c ei np e r c e n t a g ec o n t r o lo fL D L - Cl e v e l s
between baseline and the end of the study will be
assessed using the McNemar test. To assess the
improvement of control of c-LDL an analysis of covar-
iance using logistic regression will be carried out. Subse-
quently, a multilevel logistic regression model will be
developed. The main independent variable in the both
models will be “intervention”,a d j u s t e df o rb a s e l i n e
values and potential confounders. Physician will be con-
sidered a cluster in the multilevel regression).
Ethical aspects
The presented project has been evaluated by the Clinical
Research Ethics Committee of the primary care research
institute, IDIAP Jordi Gol, Barcelona June 12, 2009 (Ref:
P09/25). Since the project examines specific information
about the illness control and the information was
obtained anonymously from a population approach
(before and after intervention), the Committee did not
consider necessary to require the Informed Consent.
The intervention was applied to all patients and there
were not neither comparative groups nor randomized
distribution.
The study guarantees the confidentiality of profes-
sionals’ data. The data collected and generated will be
included in two databases as a data decoupling proce-
dure to adhere to data protection legislation and to
maintain individual privacy. For this reason there will be
different types of files, each with a different password to
be renewed periodically and which shall only be accessi-
ble by a responsible person.
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each patient is assigned a unique code. The second file
will include the patient codes linked to the main clinical
variables relevant to the study that will include the
results of the study and the clinical variables for statisti-
cal analysis. The databases will remain stored on a hard
disk of a PC with a renewable password located in a
locked office with controlled access.
Forecast execution dates
The project will be carried out over three years.
September 2009: presentation of training material,
standardized training for trainers.
January 2010: classroom and face-to-face satisfaction
survey.
March 2010-June 2010: on-line course.
January 2011-March 2011: post-intervention analysis
of results.
May 2011 Feed-back and reminder of GPC.
January 2012-September 2012: data processing, statis-
tical analysis, data interpretation, preparation and disse-
mination of results.
Discussion
The limitations of the project are that it is a before-and-
after intervention study without a control group, rando-
misation or masking. No control group has been pro-
posed in order to ensure that the educational
intervention reaches the maximum number of
professionals.
Presential training courses are being undertaken by
both physicians in hospitals (cardiologists and internists)
and primary care settings, since both groups are respon-
sible for the diagnosis and monitoring of patients with
IHD.
In fact, all the 11 PCAs have two referral laboratories
for the determination of the LDL-C but both offer the
same quality guarantees for this value determination.
Another limitation may be that the follow-up period is
insufficiently long to detect changes in morbidity and
mortality and prescription habits of physicians. How-
ever, we hope to detect at least a trend towards an
improvement in our results.
Previous studies of the implementation of guidelines
do not show very encouraging results regarding the
overall improvement of the quality of patient care but
do indicate an increase in drug prescription [11,12].
This project is interesting because vascular disease has
a high morbidity and mortality. In the Spanish popula-
tion as a whole, this has been the leading cause of death
for many decades. It causes severe disability among the
population and is responsible for a substantial increase
in healthcare costs.
Statins are the drugs of first choice for the treatment
of DL in patients with IHD and have been shown to
reduce cardiovascular morbidity and mortality. They are
also easy to use and have a good clinical safety profile.
Despite the evidence of the need to achieve a LDL-C
level of ≤ 100 mg/dl for patients with IHD, this occurs
in only 35% of patients in our area (2008 data). The col-
laboration between primary care and hospital units with
the help of the aforementioned methodology seeks to
achieve a degree of control sufficient to decrease mor-
bidity and mortality among these patients, as well as to
clear the way for the development of consensual guide-
lines to unify patient management criteria and signifi-
cantly improve the health of our population.
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